New avenues for overcoming tuberculosis drug resistance

Apr 27, 2010

Tuberculosis (TB) continues to be a global health problem, in part due to the exceptional drug resistance displayed by the TB-causing agent, Mycobacterium tuberculosis. Beyond even acquired drug resistance, these bacteria are also inherently resistant to many other common antibiotics, which limits the available options in finding alternative treatments to resistant TB strains.

However, in a presentation at the American Society for Biochemistry and Molecular Biology's annual meeting, titled " in ," John Blanchard of the Albert Einstein College of Medicine will discuss his group's work at eliminating this inherent drug resistance, which may help in the battle against the emerging extensively-drug resistant TB strains. The talk will take place on Tuesday, April 27 at 9:55 am PST in Anaheim Convention Center Room 304C.

"These XDR strains are even more resilient than multi-drug resistant (MDR) strains," notes Blanchard. They are resistant to almost everything we currently have in the kitchen."

Blanchard, a professor at Albert Einstein's department of biochemistry, and his team have specifically targeted an enzyme called beta-lactamase, which can break down and disable beta-lactams, a large family of antibiotics that includes penicillin and its relatives.

"When the M. tuberculosis genome was sequenced a few years ago, the presence of this beta-lactamase enzyme was discovered," Blanchard says, "which was surprising since beta-lactams have never been systematically used to treat TB."

Perhaps just as surprising was that most scientists didn't pay much attention to the M. tuberculosis beta-lactamase discovery, but Blanchard thought it would be an attractive , considering several beta-lactamase inhibitors had been developed for other bacteria.

"If we could inactivate this inactivator enzyme, it would expose to a whole new range of antibiotics," he says.

While M. tuberculosis was resistant to most beta-lactamase inhibitors, Blanchard's group found that the drug clavulanate was effective in shutting down the TB enzyme. The combination of clavulanate with the beta-lactam meropenem could effectively sterilize laboratory cultures of TB within two weeks, including several XDR-strains.

Blanchard notes this finding was exciting since, despite such high rates of drug resistance, research into new TB drugs is not a high priority in industrialized countries (for socio-economic reasons), and thus the best short-term approach might be identifying other already FDA approved antibiotics that are effective against TB -like meropenem and clavulanate.

Blanchard is currently progressing with the next steps of the therapeutic process, which includes both detailed animal studies and setting up some small-scale trials with XDR-TB patients in developing nations.

Explore further: Dallas hospital confirms first Ebola case in US

add to favorites email to friend print save as pdf

Related Stories

WHO warns of drug-resistant TB

Sep 06, 2006

The World Health Organization in Switzerland has warned of a new strain of tuberculosis that is rapidly spreading and cannot be treated with current drugs.

WHO: Money, drugs needed to rein in new TB strains

Mar 23, 2009

(AP) -- More money and better science are urgently needed to rein in new strains of tuberculosis that are tough or nearly impossible to treat, the WHO announced Monday in China, where the disease has long been a leading ...

Drug-resistant tuberculosis rife in China

Dec 11, 2008

Levels of drug-resistant tuberculosis (TB) in China are nearly twice the global average. Nationwide research published in the open access journal BMC Infectious Diseases has shown that almost 10% of Chinese TB cases are re ...

Recommended for you

Dallas hospital confirms first Ebola case in US

6 minutes ago

A patient at a Dallas hospital has tested positive for Ebola, the first case of the disease to be diagnosed in the United States, federal health officials announced Tuesday.

First case of Ebola diagnosed in US

1 hour ago

The United States has diagnosed its first case of the deadly Ebola virus in a man who became infected in Liberia and traveled to Texas, US health officials said Tuesday.

Study finds acupuncture does not improve chronic knee pain

2 hours ago

Among patients older than 50 years with moderate to severe chronic knee pain, neither laser nor needle acupuncture provided greater benefit on pain or function compared to sham laser acupuncture, according to a study in the ...

Ebola outbreak nears end in Nigeria

2 hours ago

The Ebola outbreak in Nigeria is almost over, US health officials said Tuesday, in a rare sign of authorities turning the tide on the highly contagious disease that has killed more than 3,000 in West Africa.

User comments : 0